OncoCyte Corporation (OCX) Tops Q2 EPS by 27c

OncoCyte Corporation (NASDAQ: OCX) reported Q2 EPS of ($1.03), $0.27 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $362.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• AutoZone beats profit view but misses on revenue
• AI and earnings keep driving markets as focus shifts to Trump-Xi summit